- Home
- LOMA vs PRCT Comparison
LOMA vs PRCT Comparison
Compare LOMA & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | PRCT |
|---|---|---|
| Founded | 1926 | 2009 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LOMA | PRCT |
|---|---|---|
| Price | $9.92 | $24.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $15.00 | ★ $35.44 |
| AVG Volume (30 Days) | 318.7K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | $22.92 | $32.85 |
| Revenue Next Year | $25.84 | $24.66 |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $7.04 | $19.35 |
| 52 Week High | $14.17 | $64.89 |
Technical Indicators
Market Signals| Indicator | LOMA | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 32.02 | 38.21 |
| Support Level | $7.26 | $19.35 |
| Resistance Level | $12.33 | $29.24 |
| Average True Range (ATR) | 0.47 | 1.80 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 16.49 | 54.74 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.